The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Abstract Background For patients presenting with an aneurysmal subarachnoid hemorrhage (aSAH), delayed cerebral ischemia (DCI) is a significant cause of morbidity and mortality. The REACT study is designed to assess the safety and efficacy of clazosentan in preventing clinical deterioration due to D...

Full description

Bibliographic Details
Main Authors: Nicolas Bruder, Randall Higashida, Hugues Santin-Janin, Cécile Dubois, E. François Aldrich, Angelina Marr, Sébastien Roux, Stephan A. Mayer
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Neurology
Subjects:
Aneurysm
Subarachnoid hemorrhage
Cerebral vasospasm
Delayed cerebral ischemia
Clazosentan
Online Access:https://doi.org/10.1186/s12883-022-03002-8

Internet

https://doi.org/10.1186/s12883-022-03002-8

Similar Items